MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597493 | Name: Melanotan-II

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Melanotan-II is a synthetic cyclic heptapeptide, an analog of alpha-melanotropin (4,10); capable of stimulating melanin synthesis & promoting rapid tanning of skin; currently in trials for use in the prevention of sunlight-induced skin cancer.

Chemical Structure

Melanotan-II
Melanotan-II
CAS#121062-08-6 (free base)

Theoretical Analysis

MedKoo Cat#: 597493

Name: Melanotan-II

CAS#: 121062-08-6 (free base)

Chemical Formula: C50H69N15O9

Exact Mass: 1023.5403

Molecular Weight: 1024.19

Elemental Analysis: C, 58.64; H, 6.79; N, 20.51; O, 14.06

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
Melanotan II acetate 121062-08-6 (free base)
Synonym
Melanotan-II; Melanotan II; MelanotanII;
IUPAC/Chemical Name
(3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide
InChi Key
JDKLPDJLXHXHNV-MFVUMRCOSA-N
InChi Code
1S/C50H69N15O9/c1-3-4-16-36(59-29(2)66)44(69)65-41-25-42(67)55-20-11-10-18-35(43(51)68)60-47(72)39(23-31-26-57-34-17-9-8-15-33(31)34)63-45(70)37(19-12-21-56-50(52)53)61-46(71)38(22-30-13-6-5-7-14-30)62-48(73)40(64-49(41)74)24-32-27-54-28-58-32/h5-9,13-15,17,26-28,35-41,57H,3-4,10-12,16,18-25H2,1-2H3,(H2,51,68)(H,54,58)(H,55,67)(H,59,66)(H,60,72)(H,61,71)(H,62,73)(H,63,70)(H,64,74)(H,65,69)(H4,52,53,56)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
SMILES Code
O=C(N[C@H](Cc1ccccc1)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N[C@H](C(N)=O)CCCCNC(C[C@H](NC([C@@H](NC(C)=O)CCCC)=O)C(N2)=O)=O)=O)Cc(c[nH]3)c4c3cccc4)=O)=O)[C@@H]2Cc5[nH]cnc5
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,024.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228(1):34-6. doi: 10.1159/000356389. Epub 2013 Dec 18. PubMed PMID: 24355990. 2: Breindahl T, Evans-Brown M, Hindersson P, McVeigh J, Bellis M, Stensballe A, Kimergård A. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015 Feb;7(2):164-72. doi: 10.1002/dta.1655. Epub 2014 Apr 25. PubMed PMID: 24771717. 3: Monge-Roffarello B, Labbe SM, Lenglos C, Caron A, Lanfray D, Samson P, Richard D. The medial preoptic nucleus as a site of the thermogenic and metabolic actions of melanotan II in male rats. Am J Physiol Regul Integr Comp Physiol. 2014 Jul 15;307(2):R158-66. PubMed PMID: 24808495. 4: Olney JJ, Sprow GM, Navarro M, Thiele TE. The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51. doi: 10.1016/j.npep.2013.11.001. Epub 2013 Nov 15. PubMed PMID: 24290566; PubMed Central PMCID: PMC3946855. 5: Navarro M, Carvajal F, Lerma-Cabrera JM, Cubero I, Picker MJ, Thiele TE. Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice. Alcohol Clin Exp Res. 2015 Aug;39(8):1425-33. doi: 10.1111/acer.12774. Epub 2015 Jun 24. PubMed PMID: 26108334; PubMed Central PMCID: PMC4515169. 6: Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). 2012 Dec;50(10):1169-73. doi: 10.3109/15563650.2012.740637. Epub 2012 Nov 5. PubMed PMID: 23121206. 7: Burian E, Burian E. [Eruptive nevi after injection of drugs marketed as melanotan II. The first two Swedish cases described]. Lakartidningen. 2013 Jan 30-Feb 5;110(5):208-10. Swedish. PubMed PMID: 23451671. 8: van den Heuvel JK, Eggels L, van Rozen AJ, Fliers E, Kalsbeek A, Adan RA, la Fleur SE. Inhibitory Effect of the Melanocortin Receptor Agonist Melanotan-II (MTII) on Feeding Depends on Dietary Fat Content and not Obesity in Rats on Free-Choice Diets. Front Behav Neurosci. 2015 Dec 24;9:358. doi: 10.3389/fnbeh.2015.00358. eCollection 2015. PubMed PMID: 26733840; PubMed Central PMCID: PMC4689860. 9: Mahiques-Santos L. [Melanotan]. Actas Dermosifiliogr. 2012 May;103(4):257-9. doi: 10.1016/j.ad.2011.08.002. Epub 2011 Nov 1. Spanish. PubMed PMID: 22051769. 10: Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84. PubMed PMID: 8637402. 11: Ter Laak MP, Brakkee JH, Adan RA, Hamers FP, Gispen WH. The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Eur J Pharmacol. 2003 Feb 21;462(1-3):179-83. PubMed PMID: 12591111. 12: Ong S, Bowling J. Melanotan-associated melanoma in situ. Australas J Dermatol. 2012 Nov;53(4):301-2. doi: 10.1111/j.1440-0960.2012.00915.x. Epub 2012 Jun 22. PubMed PMID: 22724573. 13: De Jonghe BC, Hayes MR, Zimmer DJ, Kanoski SE, Grill HJ, Bence KK. Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency. Am J Physiol Endocrinol Metab. 2012 Sep 1;303(5):E644-51. doi: 10.1152/ajpendo.00009.2012. Epub 2012 Jul 3. PubMed PMID: 22761160; PubMed Central PMCID: PMC3468506. 14: Wolters FL, de Vocht TF, Klis SF, Hamers FP, Smoorenburg GF. Co-treatment with melanotan-II, a potent melanocortin, does not protect against cisplatin ototoxicity. Hear Res. 2002 Oct;172(1-2):110-7. PubMed PMID: 12361873. 15: Giuliano F, Clément P, Droupy S, Alexandre L, Bernabé J. Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat. Neuroscience. 2006;138(1):293-301. Epub 2005 Dec 19. PubMed PMID: 16360286. 16: Rössler AS, Pfaus JG, Kia HK, Bernabé J, Alexandre L, Giuliano F. The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat. Pharmacol Biochem Behav. 2006 Nov;85(3):514-21. Epub 2006 Nov 20. PubMed PMID: 17113634. 17: Wang J, Ling S, Usami T, Murata T, Narita K, Higuchi T. Effects of ghrelin, corticotrophin-releasing hormone, and melanotan-II on food intake in rats with paraventricular nucleus lesions. Exp Clin Endocrinol Diabetes. 2007 Nov;115(10):669-73. PubMed PMID: 18058602. 18: Giuliano F, Rössler AS, Clément P, Droupy S, Alexandre L, Bernabé J. The use of telemetry technology to test the proerectile effect of melanotan-II (MT-II) in conscious rats. Eur Urol. 2005 Jul;48(1):145-51; discussion 151-2. Epub 2005 Mar 20. PubMed PMID: 15967265. 19: Kilpeläinen M, Mönkäre J, Vlasova MA, Riikonen J, Lehto VP, Salonen J, Järvinen K, Herzig KH. Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery. Eur J Pharm Biopharm. 2011 Jan;77(1):20-5. doi: 10.1016/j.ejpb.2010.10.004. Epub 2010 Oct 20. PubMed PMID: 20965250. 20: Lan EL, Ugwu SO, Blanchard J, Fang X, Hruby VJ, Sharma S. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. J Pharm Sci. 1994 Aug;83(8):1081-4. PubMed PMID: 7983590.